Dr. Yuichi Ando, Nagoya University Hospital, Japan
- Wed Sep 25 8:00 AM - 9:00 AM Imperial ARoundtable R2503: How To Utilize The UGT1A1 Genotype Testing For Individualized Irinotecan Dosage
Yuichi Ando has been a professor of the Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan, since May 2012, making full contribution to medical care, professional education and research in cancer chemotherapy. Dr. Ando received M.D. from the Nagoya University School of Medicine, Nagoya in 1990. Following completing his residency training in internal medicine at the Japanese Red Cross Nagoya First Hospital, Nagoya, and board certifications in internal medicine and respiratory medicine, Dr. Ando received Ph.D. in Medical Science from the Graduate School of Nagoya University, Nagoya, in 1999. During his Ph.D. program, Dr. Ando was trained for molecular pharmacology at Hokkaido University, Sapporo, Japan. Dr. Ando completed his postdoctoral fellowships as a Research Fellow of Japan Society of the Promotion of Science, Japan, and as a visiting fellow of the National Institute of Health, Bethesda, MD, from 1999 to 2002. His interests include developing cancer chemotherapy based on clinical pharmacology and conducting early-phase clinical trials of anticancer agents under development. Dr. Ando is the recipient of 2004 Incitement Award of the Japanese Cancer Association and 2002 Merit Award of the American Society of Clinical Oncology. Dr. Ando is a fellow of the Japanese Society of Medical Oncology and a Diplomate, Subspecialty Board of Medical Oncology.